- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05169229
Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement. (ABOGRAFT)
Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement. The ABOGRAFT Trial
Total hip replacement is the most successful treatment modern healthcare can offer patients to regain quality of life. Periprosthetic joint infection (PJI) is the most common and devastating complication after total hip replacement (THR). Between 0.5 to 2% of primary THR (first time hip replacement), and 8-10% of revision THR (replacement of a hip prosthesis) will become infected.1 The introduction of local antibiotics blended into bone cement has led to a reduction in postoperative infection in primary THR by half.2 Unfortunately, cement can't always be used in relevant quantities.
The number of primary and revision surgeries of the hip is projected to increase dramatically. Therefore, the need for a feasible infection prophylaxis that is applicable for complex primary and revision THR in addition to antibiotics loaded cement is urgent.
Impacted morselized bone allograft is often used in (revision) THR to fill bone defects. Morselized allograft has been used as a carrier for local antibiotic treatment in multiple pilot studies and appears to be an attractive and effective treatment option, both for already infected joints and as a prophylactic measure in high-risk patients (e.g. THR revision surgeries). Nonetheless, a pivotal trial to support its use in THR is lacking. The aim of this pragmatic randomized controlled double blinded drug trial is to investigate whether antibiotic impregnated bone graft (AIBG) decreases the risk of infection after hip arthroplasty compared to controls treated with placebo impregnated bone graft. Patients scheduled for elective THR will be randomized to receive AIBG or a placebo impregnated bone graft. The primary outcome variable will be the number of re-operations due to infections and PJI diagnoses 2 years postoperative.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Daphne Wezenberg, PhD
- Phone Number: 0046101030000
- Email: daphne.wezenberg@liu.se
Study Locations
-
-
Region Östergotland
-
Linköping, Region Östergotland, Sweden, 58185
- Recruiting
- Universitetssjukhuset Linköping
-
Contact:
- daphne Wezenberg, PhD
- Phone Number: 0046 793345789
- Email: daphne.wezenberg@liu.se
-
Contact:
- Jörg Schilcher, MD, PhD, Prof.
- Phone Number: 0046 101034312
- Email: jorg.schilcher@liu.se
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- Hip arthroplasty requiring bone graft
- Willing to provide informed consent.
- For women of childbearing potential; a negative pregnancy test prior to reoperation.
Exclusion Criteria:
- Ongoing prosthetic joint infection
- Known allergies and contraindications for the use of vancomycin or tobramycin
- Mental inability, reluctance, or language difficulties that according to investigator judgement, result in difficulty understanding the meaning of study participation
- Expected difficulties to complete 2-year follow-up
- Women of child bearing potential not using contraception
- Pregnant women
- Nursing women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment arm
Combination of vancomycin and tobramycin mixed with allograft and locally administered during revision surgery after total hip arthroplasty.
|
1 g vancomycin (powder) diluted in 8 ml tobramycin (80mg/ml).
Added to the prepared allograft before the allograft is used during the revision surgery.
Other Names:
|
Placebo Comparator: Placebo
Saline locally added to allograft and locally administered during revision surgery after total hip arthroplasty.
|
As a placebo added to the allograft.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reoperation due to infection or diagnosed PJI with bacteria that are sensitive to either vancomycin or tobramycin, in the same hip joint, within two years after hip arthroplasty.
Time Frame: 2 years after finalizing data collection.
|
Reoperation due to infection or diagnosed PJI 2 years of revision surgery.
|
2 years after finalizing data collection.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time and cause for reoperation for any reason within 2 and 5 years
Time Frame: 2 and 5 years after finalizing data collection.
|
Time and cause for reoperation for any reason within 2 and 5 years
|
2 and 5 years after finalizing data collection.
|
Time and cause for implant revision due to any reason within 2 and 5 years
Time Frame: 2 and 5 years after finalizing data collection.
|
Time and cause for implant revision due to any reason within 2 and 5 years
|
2 and 5 years after finalizing data collection.
|
Type of microbe and antibiotic resistance pattern for cases complicated with postoperative infection
Time Frame: 2 and 5 years after finalizing data collection.
|
Type of microbe and antibiotic resistance pattern for cases complicated with postoperative infection
|
2 and 5 years after finalizing data collection.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Differences between the two experimental groups regarding the frequencies of adverse events
Time Frame: 2 and 5 years after finalizing data collection.
|
Differences between the two experimental groups regarding the frequencies of adverse events
|
2 and 5 years after finalizing data collection.
|
Differences between the two experimental groups regarding the rates of revision due to aseptic loosening
Time Frame: 2 and 5 years after finalizing data collection.
|
Differences between the two experimental groups regarding the rates of revision due to aseptic loosening
|
2 and 5 years after finalizing data collection.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jörg Schilcher, PhD, Linkoeping University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABOGRAFT-01
- 2021-001708-14 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prosthetic Joint Infection
-
Charite University, Berlin, GermanyUnknownHip Prosthetic Joint Infection | Knee Prosthetic Joint Infection | Shoulder Prosthetic Joint Infection
-
Osteal Therapeutics, Inc.Active, not recruitingProsthetic-joint InfectionUnited States
-
University Hospital, Basel, SwitzerlandActive, not recruitingProsthetic-joint InfectionSwitzerland
-
Vivantes Netzwerk für Gesundheit GmbHUnknownProsthetic Joint Infection | Infections Joint Prosthetic | Wear of Articular Bearing Surface of Internal Prosthetic Joint | Infection Prosthetic | Prosthetic PainGermany
-
University Hospital, ToursPfizer; International Clinical Trials AssociationUnknownEfficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection (LIZ-BONE)Hip Prosthetic Joint InfectionFrance, Spain, Italy
-
University Hospital, MontpellierNot yet recruitingProsthetic-joint Infection
-
Leiden University Medical CenterRadboud University Medical Center; University Medical Center Groningen; Erasmus... and other collaboratorsRecruitingProsthetic-joint Infection | Infection Hip | Infection; Knee, JointNetherlands
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
Arrevus Inc.TerminatedProsthetic Joint Infections of Hip | Prosthetic Joint Infections of Knee | Infected SpacersUnited States
-
Technical University of MunichUnknownDiagnosis Prosthetic Joint InfectionGermany
Clinical Trials on Saline
-
Vanderbilt University Medical CenterActive, not recruitingPostural Tachycardia SyndromeUnited States
-
Johns Hopkins UniversityCystic Fibrosis FoundationCompletedCystic Fibrosis
-
University Hospital Inselspital, BerneCompletedCardiovascular Diseases | Valvular Heart DiseaseSwitzerland
-
Imam Abdulrahman Bin Faisal UniversityUnknownOtorhinolaryngologic Diseases | RhinosinusitisSaudi Arabia
-
Aalborg UniversityThe Danish Rheumatism AssociationCompleted
-
Dr. Michael FlavinWithdrawn
-
Szpital im. Św. Jadwigi ŚląskiejRecruiting
-
Makassed General HospitalCompletedLength of Hospital StayLebanon
-
Qassim UniversityCompletedApical Periodontitis | Post Operative Pain | Dental Pulp NecrosesSaudi Arabia
-
University of Washington, the Collaborative Health...Cystic Fibrosis FoundationCompleted